Application of PGK1 inhibitor in preparation of medicine for preventing and / or treating acute pancreatitis

The PGK1 inhibitor NG52 inhibits PGK1 expression and reactive oxygen generation, which solves the specific problems of acute pancreatitis treatment, significantly improves inflammatory response and oxidative stress, and provides new drug development directions and clinical application prospects.

CN119033789APending Publication Date: 2024-11-29YANGZHOU FIRST PEOPLES HOSPITAL +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410861619.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-28
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The treatment of acute pancreatitis lacks specific methods, and the prior art is difficult to effectively prevent and treat early damage and inflammatory responses of acinar cells, resulting in unpredictable conditions and poor treatment effects.

Method used

The PGK1 inhibitor NG52 is developed to reduce pancreatic inflammation and oxidative stress by inhibiting PGK1 expression and the production of reactive oxygen species, and is used to prepare drugs to prevent and treat acute pancreatitis.

Benefits of technology

NG52 significantly improved the inflammatory response and oxidative stress of acute pancreatitis, alleviated acinar cell damage and inflammatory cell infiltration, and provided a new drug development direction, with strong pharmacological effects and clinical application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033789A_ABST
    Figure CN119033789A_ABST
Patent Text Reader

Abstract

The invention discloses application of a PGK1 inhibitor in preparation of a medicine for preventing and / or treating acute pancreatitis. By simulating two in-vivo AP models related to clinic, it is proved that the occurrence and development of the two AP models can be remarkably improved when the PGK1 inhibitor NG52 is injected into the mouse body through the stomach. Meanwhile, an in-vitro AP model adopted by the invention is as follows: cell injury is caused by incubation of mouse primary acinus cells by using cholecystokinin (CCK), and cell ROS generation can be obviously inhibited and acinus cell death (LDH release) can be reduced by using a PGK1 inhibitor NG52 for incubation, so that generation and development of AP are inhibited. Therefore, the invention proposes that the PGK1 inhibitor NG52 can be applied to research, development and preparation of medicines for clinically preventing / treating AP for the first time.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biomedicine, and in particular relates to the use of a PGK1 inhibitor in the preparation of a medicine for preventing and / or treating acute pancreatitis. Background Art

[0002] Acute pancreatitis (AP) is an acute inflammation of the pancreas with acinar cell damage as the main pathophysiological change. The incidence of AP is increasing year by year worldwide, causing a huge burden on medical resources and socioeconomic burden. Although most AP patients present with a mild clinical self-limiting state, a small number of patients still suffer from pancreatic necrosis and infection due to persistent pancreatic inflammation and endotoxemia. What's more, some patients are accompanied by complications such as systemic inflammatory response syndrome (SIRS) and multiple systemic organ failure (MSOF), and the severity and mortality rates remain high [1-3]. The activation of zymogen in the acinus is accompanied by the release of intracellular factors and proinflammatory mediators, which trigger the molecular cascade events of AP disease. At present, there is no specific treatment in clinical practice. The diagnosis and treatment plan attempts to alleviate AP by blocking inflammatory mediators, but due to its high variability and unpredictability, it has little effect. Therefore, how to find drugs for early prevention and early treatment of early acinar cell damage / death is the key to clinical improvement of AP [4-5].

[0003] In recent years, pancreatic metabolic disorders have been shown to be crucial in the onset and progression of AP, and the intracellular metabolic state is closely related to acinar cell damage. Anaerobic glycolysis is one of the key intracellular metabolic pathways by which cells convert the biochemical energy of nutrients into adenosine triphosphate (ATP) for cellular energy supply. Phosphoglycerate kinase 1 (PGK1) is the first enzyme in the glycolysis pathway to produce ATP. It catalyzes the transfer of high-energy phosphate from 1,3-bisphosphoglycerate (1,3-BPG) to ADP, thereby producing 3-phosphoglycerate and ATP[8-9]. PGK1 plays an important role in regulating energy metabolism, biosynthesis, and redox balance by controlling ATP and 3-PG levels[6]. PGK1 expression is upregulated in a variety of human diseases, including autoimmune myocarditis[7], glioma[8], rheumatoid arthritis[9], pancreatic ductal adenocarcinoma

[10] , and hepatocellular carcinoma

[11] . Studies have found that PGK1 depletion can activate the Keap1 / Nrf2 signaling pathway, which protects osteoblasts / osteocytes from dexamethasone damage by resisting ROS generation and inhibiting oxidative stress levels

[12] . These studies suggest that PGK1 may be involved in the pathogenesis of inflammatory diseases.

[0004] However, the role of PGK1 in AP is still unclear. Oxidative stress is the main factor leading to pancreatic damage in AP[13-14]. In the early stages of AP, reactive oxygen species (ROS) accumulate in pancreatic acinar cells and immune cells, aggravating the state of tissue damage

[13] . This requires targeting oxidative stress as a possibility to alleviate AP disease. Currently, many studies have confirmed that inhibiting oxidative stress by providing exogenous antioxidants or activating endogenous antioxidant mechanisms can protect AP[15-17]. Excessive ROS generation can lead to cell damage, increased oxidative stress pressure, significant changes in key enzymes of glycolysis and water metabolism, and regulate the occurrence and development of diseases such as tumors and myocardial injury.

[0005] The function and molecular regulatory mechanism of PGK1 in AP are still unknown, and there is currently no existing technology reporting the relevant biological effects of the PGK1 inhibitor NG52 in AP.

[0006] References:

[0007] [1]E.de-Madaria,JLBuxbaum,Advances in the management of acutepancreatitis,Nature reviews.Gastroenterology&hepatology 20(2023)691-692.10.1038 / s41575-023-00808-w.

[0008] [2]DMSpagnolo,PJGreer,CSOhlsen,et al.,Acute and ChronicPancreatitis Disease Prevalence,Classification,and Comorbidities:A CohortStudy of the UK BioBank,Clinical and translational gastroenterology 13(2022)e00455.10.14309 / ctg.0000000000000455.

[0009] [3] P. Szatmary, T. Grammatikopoulos, W. Cai, et al., Acute Pancreatitis: Diagnosis and Treatment, Drugs 82 (2022) 1251-1276.10.1007 / s40265-022-01766-4.

[0010] [4]Q.Zhu,C.Yuan,X.Dong,et al.,Bile acid metabolomics identifieschenodeoxycholic acid as a therapeutic agent for pancreatic necrosis,Cellreports.Medicine 4(2023)101304.10.1016 / j.xcrm.2023.101304.

[0011] [5]R.Wang,Y.Wang,Y.Tao,et al.,Temporal Proteomic and LipidomicProfiles of Cerulein-Induced Acute Pancreatitis Reveal Novel Insights forMetabolic Alterations in the DiseasePathogenesis,ACS omega 8(2023)12310-12326.10.1021 / acsomega.3c00019.

[0012] [6]S.Wang,B.Jiang,T.Zhang,et al.,Insulin and mTOR Pathway RegulateHDAC3-MediatedDeacetylation and Activation of PGK1,PLoS biology 13(2015)e1002243.10.1371 / journal.pbio.1002243.

[0013] [7]Y.Lu,N.Zhao,Y.Wu,et al.,Inhibition of phosphoglycerate kinase 1attenuates autoimmunemyocarditis by reprogramming CD4+T cell metabolism,Cardiovasc Res 119(2023)1377-1389.10.1093 / cvr / cvad029.

[0014] [8]W.L.Wang,Z.R.Jiang,C.Hu,et al.,Pharmacologically inhibitingphosphoglycerate kinase1 for glioma with NG52,Acta Pharmacol Sin 42(2021)633-640.10.1038 / s41401-020-0465-8.

[0015] [9]Y.Zhao,X.Yan,X.Li,et al.,PGK1,a glucose metabolism enzyme,may playan importantrole in rheumatoid arthritis,Inflamm Res 65(2016)815-825.10.1007 / s00011-016-0965-7.

[0016]

[10] T.L.Hwang,Y.Liang,K.Y.Chien,J.S.Yu,Overexpression and elevatedserum levels ofphosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma,Proteomics 6(2006)2259-2272.10.1002 / pmic.200500345.

[0017]

[11] H.Hu,W.Zhu,J.Qin,et al.,Acetylation of PGK1 promotes liver cancercell proliferationand tumorigenesis,Hepatology 65(2017)515-528.10.1002 / hep.28887.

[0018]

[12] J.Liang,X.Y.Zhang,Y.F.Zhen,et al.,PGK1 depletion activates Nrf2signaling to protecthuman osteoblasts from dexamethasone,Cell death&disease10(2019)888.10.1038 / s41419-019-2112-1.

[0019]

[13] Y.Ren,W.Liu,L.Zhang,et al.,Milk fat globule EGF factor 8 restoresmitochondrialfunction via integrin-medicated activation of the FAK-STAT3signaling pathway in acutepancreatitis,Clin Transl Med 11(2021)e295.10.1002 / ctm2.295.

[0020]

[14] D.N.Criddle,Reactive oxygen species,Ca(2+)stores and acutepancreatitis;a step closerto therapy?,Cell calcium 60(2016)180-189.10.1016 / j.ceca.2016.04.007.

[0021]

[15] Y.Ren,J.Zhang,M.Wang,et al.,Identification of irisin as atherapeutic agent that inhibits oxidative stress and fibrosis in a murinemodel of chronic pancreatitis,Biomedicine&pharmacotherapy=Biomedecine&pharmacotherapie 126(2020)110101.10.1016 / j.biopha.2020.110101.

[0022]

[16] R.Chen,T.Hornemann,S. et al.,Serine administration as anovel prophylactic approach to reduce the severity of acute pancreatitisduring diabetes in mice,Diabetologia 63(2020)1885-1899.10.1007 / s00125-020-05156-x.

[0023]

[17] L. Kong, J. Deng, Summary of the invention

[0024] In order to overcome the above-mentioned shortcomings of the prior art, the purpose of the present invention is to clarify the role of PGK1 in AP and the preventive and therapeutic effects of its inhibitor NG52 on pancreatic necrosis and inflammatory response in AP.

[0025] In order to achieve the above object, the present invention adopts the following technical solutions:

[0026] The present invention discloses, on one hand, the use of a PGK1 inhibitor in the preparation of a drug for preventing and / or treating acute pancreatitis.

[0027] Preferably, the PGK1 inhibitor is NG52, and the molecular formula of NG52 is C 16 H 19 C1N 6O , the structural formula is as follows:

[0028]

[0029] NG52 is a trisubstituted purine that is a cell-permeable, reversible, and ATP-competitive inhibitor of the cell cycle-regulated kinase Cdc28p with an IC50 of 7 μM. NG52 binds to the ATP-binding site of yeast cyclin-dependent kinases and is able to inhibit Cdc28p and Pho85p.

[0030] Preferably, the drug is a drug that inhibits the expression of PGK1.

[0031] Preferably, the drug is a drug that reduces inflammatory cell infiltration in pancreatic tissue.

[0032] More preferably, the inflammatory cells include macrophages, neutrophils and the like.

[0033] Preferably, the drug is a drug that inhibits the expression level of inflammatory factors in serum, plasma and pancreatic tissue.

[0034] More preferably, the inflammatory factors include MCP-1, IL-1β and IL6.

[0035] Preferably, the drug is a drug that inhibits the generation of reactive oxygen species (ROS) and improves oxidative stress in acinar cells and / or pancreatic tissue.

[0036] Preferably, the drug is a drug that inhibits inflammatory damage to acinar cells.

[0037] On the other hand, the present invention also discloses a product, the active ingredient of which is NG52, and the uses of the product include at least one of the following uses:

[0038] a) Improve the inflammatory response of acute pancreatitis;

[0039] b) Improve the generation of reactive oxygen species (ROS) in acute pancreatitis;

[0040] c) Improve ATP production in the glycolytic pathway in acute pancreatitis;

[0041] d) inhibiting oxidative stress in acute pancreatitis;

[0042] e) inhibit the occurrence / development of acute pancreatitis;

[0043] The product includes a drug, an additive or an active ingredient.

[0044] Another aspect of the present invention also discloses a drug for preventing / treating acute pancreatitis, the drug comprising an active ingredient NG52 and pharmaceutically addable excipients;

[0045] Among them, the molecular formula of NG52 is C 16 H 19 C1N 6O , the structural formula is as follows:

[0046]

[0047] Preferably, the auxiliary materials include one or more of diluents, excipients, fillers, binders, wetting agents, disintegrants, absorption promoters, surfactants, adsorption carriers and lubricants;

[0048] The drug can be introduced into the body tissues by oral administration, injection, spray, nasal drops, eye drops, penetration, absorption, and physical or chemical mediation methods; or can be introduced into the body after being mixed or wrapped with other substances.

[0049] Compared with the prior art, the present invention has the following beneficial effects:

[0050] The present invention provides the use of PGK1 inhibitor NG52 in the preparation of drugs for inhibiting AP. The present invention simulates two clinically relevant in vivo AP models: ① intraperitoneal injection of caerulein to induce AP in C57BL / 6 mice; ② pancreatic duct ligation to induce AP in C57BL / 6 mice. Experiments have shown that oral administration of the PGK1 inhibitor NG52 to mice can significantly improve the occurrence and development of the above two AP models. At the same time, the in vitro AP model used in the present invention is: cholecystokinin (CCK) incubation of mouse primary acinar cells causes cell damage, and incubation with the PGK1 inhibitor NG52 can significantly inhibit cellular ROS generation, reduce acinar cell death (LDH release), and thus inhibit the occurrence and development of AP. Therefore, the present invention proposes for the first time that the PGK1 inhibitor NG52 can be used in the research and development and preparation of drugs for the clinical prevention / treatment of AP.

[0051] The present invention provides a PGK1 inhibitor NG52, which has strong pharmacological effects and clear therapeutic effects. The present invention provides a new drug source for preventing, diagnosing, detecting, protecting, treating and studying acute pancreatitis, and is easy to promote and apply clinically, and can generate huge clinical application prospects and social benefits in a relatively short period of time. BRIEF DESCRIPTION OF THE DRAWINGS

[0052] Figure 1 The results show that the glycolysis metabolic pathway is significantly upregulated in the AP model; A is the RAN-Seq differential gene heat map of pancreatic tissue of AP mice induced by caerulein; B is the GSEA enrichment analysis of inflammation-related pathways and oxidative stress-related pathways; C is the GSEA enrichment analysis of the glycolysis pathway; D is the heat map of key enzyme genes in the glycolysis pathway.

[0053] Figure 2 The results of the study on the changes of PGK1 in in vitro and in vivo AP models; A is the immunohistochemistry of PGK1 in pancreatic tissue; B is the mRNA expression level of PGK1 in acinar cells; C and D are the protein expression and quantification of PGK1 in acinar cells, respectively.

[0054] Figure 3 These are the experimental results that NG52 can protect acinar cell damage by inhibiting glycolysis and alleviating oxidative stress; A is the level of LDH release in the supernatant of acinar cells; B is the level of glucose in the supernatant of acinar cells; C is the level of lactate release in the supernatant of acinar cells; D and E are the immunofluorescence and scoring of ROS in acinar cells, respectively; and F is the level of ATP production in acinar cells.

[0055] Figure 4The results show that NG52 can reduce the severity of AP in mice induced by caerulein; A is the HE staining result of pancreatic tissue in mice; B is the pathological scoring result of pancreatic tissue edema; C is the pathological scoring result of pancreatic tissue inflammatory exudation; D is the pathological scoring result of pancreatic tissue acinar cell necrosis; E is the pathological scoring result of pancreatic tissue damage.

[0056] Figure 5 NG52 can alleviate the serum amylase and lipase levels of AP in mice induced by caerulein; A is the change of serum amylase level; B is the change of serum lipase level;

[0057] Figure 6 NG52 can reduce the level of inflammatory factors in AP of mice induced by caerulein; wherein, A is the level of IL-1β inflammatory factor; B is the level of MCP-1 inflammatory factor; C is the level of IL-6 inflammatory factor.

[0058] Figure 7 The results of the experiment show that NG52 can reduce inflammatory cell infiltration in pancreatic tissue of AP mice induced by caerulein; A is the F4 / 80 immunohistochemistry and MPO immunohistochemistry of pancreatic tissue; B is the F4 / 80 immunohistochemistry score of pancreatic tissue; C is the MPO immunohistochemistry score of pancreatic tissue.

[0059] Figure 8 The results of the experiment show that NG52 can reduce the oxidative stress level in pancreatic tissue of AP mice induced by caerulein; A and B are the results of ROS immunofluorescence and its scoring, respectively; C is the GSH level in pancreatic tissue; and D is the MDA level in pancreatic tissue.

[0060] Fig. 9 The experimental results show that NG52 can reduce the severity of AP in mice induced by pancreatic duct ligation (PDL); A is the HE staining result of mouse pancreatic tissue; B is the pathological score of pancreatic tissue damage (including pancreatic tissue edema, inflammatory exudation, and acinar cell necrosis); C and D are serum amylase and lipase levels, respectively. DETAILED DESCRIPTION

[0061] In order to enable those skilled in the art to better understand the scheme of the present invention, the technical scheme in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of the present invention.

[0062] It should be noted that the terms "including" and "having" and any variations thereof in the specification and claims of the present invention and the above-mentioned drawings are intended to cover non-exclusive inclusions. For example, a process, method, system, product or apparatus comprising a series of steps or units is not necessarily limited to those steps or units clearly listed, but may include other steps or units that are not clearly listed or inherent to these processes, methods, products or apparatus.

[0063] The present invention is further described in detail below in conjunction with the accompanying drawings:

[0064] The experimental methods used in the examples of the present invention are conventional methods unless otherwise specified. The reagents and materials used in the examples can be purchased conventionally, and the quantitative experiments involved in the examples are repeated at least three times, and the results are averaged.

[0065] The C57 / BL6 mice used were purchased from the Animal Center of Nanjing Model University.

[0066] The caerulein (Cae) used was purchased from Selleck Company with the product number S9690.

[0067] The cholecystokinin (CCK) used was purchased from Echelon Biosciences with the catalog number 471-47.

[0068] The NG52 used was purchased from MCE Company with the product number HY-15465; the molecular formula of NG52 is

[0069] C 16 H 19 C1N 6O , CAS No.: 212779-48-1, the structural formula is as follows:

[0070]

[0071] Example 1: PGK1 is significantly upregulated in cerulein-induced mouse AP

[0072] 1. Cae-induced AP model in mice

[0073] Experimental animals: 6-8 week old male C57BL / 6J mice (average weight 25 g).

[0074] The experimental animals were divided into a normal control group and a model group. The APAP model was established by intraperitoneal injection of Cae (100 μg / kg, 1h interval, 7 injections) in the model group. The control group mice were given a strict PBS control intraperitoneal injection. After anesthetizing the mice, in vivo cardiac perfusion was performed to remove the circulating blood, and pancreatic tissue was quickly extracted for RNA-seq (RNA sequencing) detection.

[0075] 2. In vitro acinar cell injury model induced by CCK stimulation

[0076] Primary acinar cells from male C57BL / 6J mice 6-8 weeks in advance were inoculated in 12-well plates and cultured in Hepes medium (containing 2% FBS) at 37°C in a 5% CO2 incubator, and grouped as follows:

[0077] Control group: cultured for 6 hours;

[0078] CCK group: 5 μM CCK was added to each well and cultured for different time periods;

[0079] Cells from each group were collected, and the mRNA and protein of the cells were extracted. The mRNA and protein levels were detected by real-time quantitative PCR (qPCR) experiments and Western Blotting (WB) experiments.

[0080] Results Figure 1 A in the middle is the volcano map of differentially expressed genes in the RNA-Seq transcriptomics of the control group and the AP model group, with a total of 5360 up-regulated genes and 5133 down-regulated genes. Figure 1 As shown in Figure B, GSEA enrichment analysis using differentially expressed genes showed that inflammation-related pathways and oxidative stress-related pathways were significantly upregulated in AP, which is consistent with previous literature, indicating that the model is very successful. The results of GSEA enrichment analysis of differentially expressed genes showed that the glycolysis metabolic pathway was significantly upregulated in AP, and its key metabolic enzyme PGK1 was significantly upregulated (see Figure 1 CD). Figure 2 As shown in Figure A, the results of pancreatic tissue immunohistochemistry showed that the expression of PGK1 in acinar cells of AP mice was significantly increased. Figure 2 The mRNA and protein levels of PGK1 in acinar cells shown in BD in the middle were significantly increased in the CCK-stimulated in vitro acinar injury model, and were time-dependent, which was consistent with the results of the in vitro AP mouse model. These results show that the glycolysis metabolic pathway is significantly upregulated in the AP model, and the expression level of its key metabolic enzyme PGK1 is continuously and significantly upregulated, and is time-dependent.

[0081] Example 2: NG52 inhibits glycolysis and alleviates CCK-induced acinar cell damage

[0082] 1. NG52 inhibits glycolysis in AP acinar cells

[0083] Primary acinar cells were extracted and cultured simultaneously. The following grouping treatments were performed:

[0084] Control group: cultured for 6 hours;

[0085] CCK group: 5uM cholecystokinin (CCK) was added to each well and cultured for 6 hours;

[0086] CCK group + NG52 low, medium and high concentration groups: 5uM cholecystokinin (CCK) and 1, 2.5, 5uM NG52 were added to each well and cultured for 6 hours.

[0087] The cells and supernatant of each group were collected to detect the cellular APT production and the levels of glucose and lactate release in the supernatant.

[0088] NG52 inhibits AP acinar cell death and ROS generation

[0089] Primary acinar cells were extracted and cultured simultaneously and grouped as follows:

[0090] Control group: cultured for 6 hours;

[0091] CCK group: 5uM cholecystokinin (CCK) was added to each well and cultured for 6 hours;

[0092] CCK group + NG52 low, medium and high concentration groups: 5uM cholecystokinin (CCK) and 1, 2.5, 5uM NG52 were added to each well and cultured for 6 hours.

[0093] The cells and supernatant of each group were collected for DHE staining and LDH level detection to detect the ROS generation and death of acinar cells.

[0094] The results are as follows Figure 3 As shown, compared with the control group, the glucose level in the cell supernatant of the CCK group was decreased ( Figure 3 Middle B), the level of lactate release increases ( Figure 3 C), indicating enhanced glycolysis and the level of LDH released from the cell supernatant ( Figure 3 A) and oxidative stress ROS generation level ( Figure 3 The DF in the AP cells was significantly increased, while the application of NG52 could significantly inhibit the above-mentioned related phenomena. These results suggest that NG52 protects AP acinar cell death by inhibiting glycolysis and suppressing oxidative stress levels.

[0095] Example 3: Application of NG52 in the prevention and treatment of AP

[0096] 1. Ceruin-induced AP model in mice

[0097] According to the actual operation and model induction of Example 1, the 12h cerulein-induced model was selected for subsequent research. The modeling method was the same as that of Example 1.

[0098] 2. NG52 gavage

[0099] The NG52 drug was dissolved in CMCNa buffer (25 mg / mL). The model group mice were randomly divided into AP group, low-dose (50 mg / kg) NG52 treatment group, medium-dose (100 mg / kg) NG52 treatment group, and high-dose (200 mg / kg) NG52 treatment group (7 mice in each group). NG52 was given intragastricly 1 hour after the caerulein modeling, and the AP group was only given intragastricly CMCNa buffer. All mice were anesthetized by intramuscular injection of 50 mg / kg of Shutai 12 hours after the first intraperitoneal injection of caerulein, and the mouse serum was collected for serum enzyme levels and inflammatory factor levels. Subsequently, the mice underwent in vivo cardiac perfusion to remove the circulating blood, and the pancreatic tissue was quickly extracted for fixation and dehydration, and HE-stained paraffin sections and immunohistochemical staining were made.

[0100] The results are as follows Figure 4 As shown in Figure 2, NG52 can improve pancreatic tissue damage (edema, inflammatory exudate and acinar cell necrosis). Figure 5 and Figure 6 As shown in the results, high-dose NG52 can significantly reduce the levels of serum amylase, lipase and serum inflammatory factors (IL-1β, IL-6, MCP-1), and the degree of protection is dose-dependent.

[0101] Based on Examples 1 and 2, we observed that the level of PGK1 in acinar cells was persistently increased in cerulein-induced AP mice, and targeted inhibition of PGK1 could alleviate pancreatic necrosis and reduce AP inflammatory injury.

[0102] Example 4: NG52 can reduce inflammatory cell infiltration and oxidative stress levels in pancreatic tissue of AP mice

[0103] 1. Ceruin-induced AP model in mice

[0104] According to the actual operation and model induction of Example 1, the 12h cerulein-induced model was selected as a follow-up study. The modeling method was the same as that of Example 1.

[0105] 2. NG52 gavage

[0106] According to Example 3, high-dose (200 mg / kg) NG52 has the best preventive and therapeutic effect in AP. We selected high-dose NG52 for subsequent related experimental studies. The administration method and modeling method are the same as in Example 3. Figure 7As shown in Figure 2, high-dose NG52 can significantly improve the infiltration of macrophages (F4 / 80) and neutrophils (MPO) in pancreatic tissue of AP. Figure 8 As shown, NG52 significantly reduced ROS generation and oxidative stress levels (MDA and GSH levels) in AP pancreatic tissue.

[0107] Example 5: Application of NG52 in preventing and treating acute pancreatitis

[0108] 1. Mouse AP model induced by pancreatic duct ligation

[0109] Pancreaticobiliary duct ligation (PDL)-induced acute pancreatitis is an effective way to simulate pancreatitis caused by bile reflux in humans. Edema pancreatitis occurs 6 hours after ligation, and bleeding, necrosis, and inflammatory cell infiltration occur 12 hours later. We used this model to further clarify the preventive and therapeutic effects of NG52 in AP.

[0110] Experimental animals: 6-8 week old male mice (average weight 25g)

[0111] The experimental animals were divided into a model group and a sham operation group (10 animals in each group).

[0112] 1. Experimental animals were anesthetized by intramuscular injection of 50 mg / kg of Zotal.

[0113] 2. After all experimental animals were anesthetized, they were fixed on the operating table. The model group made a 1-2 cm longitudinal incision in the abdomen to expose the abdominal cavity, and turned the duodenum to expose its distal end. At 1 cm above the duodenal papilla, blunt dissection of the pancreatic duct surrounding tissue was performed, and the pancreatic duct was ligated with 6# silk thread. The pancreatic duct was completely blocked to simulate the gallstone pancreatitis caused by cholelithiasis, and the abdominal cavity was closed layer by layer and the skin was sutured. The sham operation group only performed the related operation of opening and closing the abdomen, and the pancreatic duct ligation operation was not performed. All mice were recovered for 30 min at a 37 degree Celsius constant temperature operating table after the operation.

[0114] 2. NG52 gavage

[0115] The model group mice were randomly divided into a vehicle group and an NG52 group (7 mice in each group). The NG52 group was given a high dose of NG52 (200 mg / kg) 1 hour after pancreatic duct ligation, and the vehicle group mice and sham-operated mice were given CMCNa by gavage. Serum was collected from all mice 12 hours after the start of modeling, and intraperitoneal injection anesthesia was performed 24 hours later, and pancreatic tissue and serum were collected for subsequent experiments.

[0116] The results are as follows Fig. 9 As shown in Figures A and B, NG52 can significantly improve pancreatic tissue damage (pancreatic tissue edema, inflammatory exudation, and acinar cell necrosis) in PDL-induced AP mice. Fig. 9As shown in Figures C and D, NG52 can reduce the levels of serum amylase and lipase in AP mice.

[0117] The above contents are only for explaining the technical idea of ​​the present invention and cannot be used to limit the protection scope of the present invention. Any changes made on the basis of the technical solution in accordance with the technical idea proposed by the present invention shall fall within the protection scope of the claims of the present invention.

Claims

1. Use of PGK1 inhibitors in the preparation of drugs for preventing and / or treating acute pancreatitis.

2. The use according to claim 1, characterized in that The PGK1 inhibitor is NG52, and the molecular formula of NG52 is C 16 H 19 C1N 6O , the structural formula is as follows:

3. The use according to claim 1 or 2, characterized in that: The drug is a drug that inhibits the expression of PGK1.

4. The use according to claim 1 or 2, characterized in that: The medicine is a medicine for reducing the infiltration of inflammatory cells in pancreatic tissue.

5. The use according to claim 1 or 2, characterized in that: The drug is a drug that inhibits the expression level of inflammatory factors in serum, plasma and pancreatic tissue.

6. The use according to claim 1 or 2, characterized in that: The drug is a drug for inhibiting the generation of reactive oxygen species (ROS) and improving oxidative stress in acinar cells and / or pancreatic tissue.

7. The use according to claim 1 or 2, characterized in that: The medicine is a medicine for inhibiting inflammatory damage of acinar cells.

8. A product, characterized in that The active ingredient of the product is NG52, and the uses of the product include at least one of the following uses: a) Improve the inflammatory response of acute pancreatitis; b) Improve the generation of reactive oxygen species (ROS) in acute pancreatitis; c) Improve ATP production in the glycolytic pathway in acute pancreatitis; d) inhibiting oxidative stress in acute pancreatitis; e) inhibit the occurrence / development of acute pancreatitis; The product includes a drug, additive or active ingredient; Among them, the molecular formula of NG52 is C 16 H 19 C1N 6O , the structural formula is as follows:

9. A drug for preventing / treating acute pancreatitis, characterized in that: The drug is composed of an active ingredient NG52 and pharmaceutically addible excipients; Among them, the molecular formula of NG52 is C 16 H 19 C1N 6O , the structural formula is as follows:

10. The drug for preventing / treating acute pancreatitis according to claim 9, characterized in that: The auxiliary materials include one or more of diluents, excipients, fillers, binders, wetting agents, disintegrants, absorption promoters, surfactants, adsorption carriers and lubricants; The drug can be introduced into the body tissues by oral administration, injection, spray, nasal drops, eye drops, penetration, absorption, and physical or chemical mediation methods; or can be introduced into the body after being mixed or wrapped with other substances.